Conflicts of Interest in United States Food and Drug Administration Advisory Committees: A Systematic Literature Review

COIs remain prevalent in FDA advisory committees, particularly among public speakers, for which they are strongly associated with favorable testimony. These findings underscore the need for stronger and more consistent COI disclosure and management policies that include both committee members and public speakers to protect decision-making integrity.